SNY Sanofi American Depositary Shares (Each representing one-half of one ordinary share) 로딩 중... : 애널리스트의 강세 및 약세 의견
REGN 실적 발표에서차트 로딩 중...
최고 콜
피드
12:30
7월 30일
7월 30일
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits. — A new, higher-margin, recurring profit share kicks in following the repayment.
높음
12:30
4월 29일
4월 29일
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue. — This is a significant, durable revenue tailwind for Regeneron from Q3 onwards.
높음
13:30
1월 30일
1월 30일
Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share. — This is a major profitability inflection point for Regeneron, as its profit share will increase materially in the second half of 2026.
높음
SNY 애널리스트 커버리지
Buzzberg는 1개 소스에서 SNY (Sanofi American Depositary Shares (Each representing one-half of one ordinary share))을 추적합니다. 애널리스트 2명의 강세 콜 0개와 약세 콜 0개가 있습니다. 심리가 팽팽하게 나뉘었습니다. 총 거래 아이디어 3개를 추적합니다. 최근 7일: 관찰 1개. 최근 발언자: Dr. Leonard Schleifer, Chris Fethmore.